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Review Article
Introduction
Postoperative anemia is a common complication in patients 
undergoing major orthopedic surgery, including elective 
total hip arthroplasty (THA) and total knee arthroplasty 
(TKA). Postoperative anemia is associated with postopera-
tive infections, poor physical function and recovery, and 
increased length of hospital stay and mortality.1 The preva-
lence of anemia at baseline in adults 65 years or older is 
11% for men and 10.2% for women, potentially leading to a 
higher rate of underlying anemia prior to elective surgery 
because of a greater incidence of THA and TKA in the 
elderly population.2,3 In patients undergoing elective THA 
or TKA, the prevalence of preoperative anemia is approxi-
mately 24.9% ± 9%, with estimations of subsequent postop-
erative anemia at 51% ± 10%.1 The pervasiveness of 
perioperative anemia in this patient population increases the 
risk for postoperative complications.
Anemia in elective orthopedic surgery is multifactorial. 
A major contributing factor related to surgery itself is 
intraoperative blood loss, which may be as significant as1 
to 2 L during the procedure.4 The acute blood loss during 
surgery and subsequent decline in oxygen delivery to vital 
tissues is often unable to be corrected by the red blood cell 
(RBC) maturation process, which typically takes 1 to 2 
weeks.5,6 Anemia may also arise as a result of a postopera-
tive inflammatory response. This leads to decreased eryth-
ropoietin (EPO) production or response inhibition, even 
with normal levels of circulating EPO. The inflammatory 
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Abstract
Objective: To assess the use of oral iron, intravenous (IV) iron, and erythropoiesis-stimulating agents (ESAs) for the 
prevention and management of perioperative anemia in elective orthopedic surgery patients, and to provide a clinical 
algorithm for use. Data Sources: A PubMed and MEDLINE search was conducted from 1964 through March 2016 using 
the following search terms alone or in combination: orthopedic, surgery, elective, anemia, blood transfusion, iron, erythropoiesis-
stimulating agents, and erythropoietin. Study Selection and Data Extraction: All English-language prospective and 
retrospective human studies and meta-analyses evaluating oral iron, IV iron, or ESA alone or in combination in elective 
orthopedic surgery patients were evaluated, provided they reported blood transfusion outcomes. Data Synthesis: A 
total of 9 prospective and retrospective studies and 1 meta-analysis were identified and included. In the preoperative 
setting, administration of oral iron, IV iron, or ESA alone or in combination to correct underlying anemia led to significantly 
reduced transfusion rates. Transfusion requirements were generally less with combination therapy (ESA + oral or IV 
iron). In the short-term perioperative or postoperative period, use of oral or IV iron led to conflicting results, with 
some reporting a statistically significant reduction in blood transfusions, whereas others reported none. Conclusions: In 
elective orthopedic surgery, IV or oral iron with or without an ESA may provide benefit in prevention of postoperative 
anemia and results in blood transfusion reduction without significantly increasing the risk of adverse events. These agents 
should be considered at the lowest effective dose with emphasis on administration prior to planned surgery.
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response has the potential to modify iron metabolism and 
decrease the body’s ability to utilize iron stores.7-9 Each 
pathway to the development of postoperative anemia must 
be considered when evaluating potential treatment strate-
gies. Additionally, certain risk factors or patient demo-
graphics have been identified as predictors for postoperative 
anemia in the overall surgery population. These include 
female sex, smaller body surface area, and African American 
racial identity.10,11 Regardless, all patients should be 
screened for anemia preoperatively and throughout the sur-
gical setting.
Correction of postoperative anemia has historically been 
focused on blood transfusions. Orthopedic surgery alone 
accounts for 10% of all packed RBC transfusions nationwide.12 
A recent observational study at a large hospital network 
found transfusion rates of 19.3% and 38.5% in patients 
undergoing TKA and THA, respectively, with considerable 
variation among surgeons.13 With blood transfusions come 
numerous complications, culminating in a high incidence of 
morbidity and mortality.12,14 From 2008 to 2012, 198 
transfusion-related mortalities were reported to the US 
Food and Drug Administration.12 Blood transfusions pose 
an increased burden on the health care system and are asso-
ciated with a number of complications and poor outcomes, 
which are listed in Table 1.12,14,15 In addition to various 
complications, there is also considerable monetary cost 
associated with transfusions. An evaluation of allogenic 
blood transfusions in patients undergoing elective THA 
found that transfusions increased total cost for patients by 
$1731 ± $49 compared with patients who did not receive 
transfusions (P < 0.001).15
Various approaches have been studied to reduce the use 
of blood transfusions to prevent transfusion-related adverse 
events, increase patient safety, and reduce cost. The 
American Association of Blood Banks (AABB) published 
clinical practice guidelines in 2012 evaluating transfusion 
thresholds in hospitalized patients.16 For postoperative sur-
gical patients who are otherwise stable, including those 
with a preexisting cardiovascular condition, the AABB rec-
ommends a traditional transfusion threshold of 8 g/dL or 
less or as needed when symptoms (chest pain, orthostatic 
hypotension, tachycardia unresponsive to fluid resuscita-
tion, or heart failure) arise. Overall, this strategy is associ-
ated with 39% fewer transfusions, with improved morbidity 
and mortality and no difference in efficacy.16 Beyond a 
transfusion threshold, additional strategies can aid in cor-
recting anemia and further mitigate the need for transfusion, 
such as the use of intravenous (IV) or oral iron therapy or 
erythropoiesis-stimulating agents (ESAs).
To date, there is no standard of care in perioperative 
management of anemia in patients undergoing elective 
THA or TKA. In this article, we discuss various approaches 
to minimize blood transfusions in patients undergoing elec-
tive orthopedic surgery, focusing on the role of IV and oral 
iron and ESA pharmacotherapy, as well as important treat-
ment considerations for the use of these agents.
Methods
An English-language literature review was performed 
through a PubMed and MEDLINE database search from 
1964 through March 2016 using the following terms alone 
or in various combinations: orthopedic, surgery, elective, 
anemia, blood transfusion, iron, erythropoiesis-stimulating 
agents, and erythropoietin. Additionally, references of rel-
evant articles were reviewed for additional studies.
Results
A total of 8 prospective and retrospective studies and 1 
meta-analysis evaluating strategies to limit blood transfu-
sions in elective orthopedic surgeries in adult patients were 
included in the review.
Prehospitalization Setting
Emphasis should be placed on prevention, prompt identifi-
cation, and correction of anemia in patients undergoing 
elective orthopedic surgery. Several strategies have been 
evaluated to achieve this in the preoperative setting. 
Initially, patients should be instructed to discontinue anti-
platelet, anticoagulant, and NSAID (nonsteroidal anti-
inflammatory drug) medications prior to surgery. Patients 
with planned elective surgeries should be screened for 
underlying anemia as soon as possible.12,17 Iron replace-
ment and ESAs have been studied preoperatively as a way 
of preemptively correcting anemia.
Preoperative iron-deficiency anemia (IDA) has been 
shown to increase transfusion requirements in the cardiac 
surgery population and remains a concern in various types 
of surgical populations.18 Correcting IDA preoperatively 
through the use of oral or IV iron may be of benefit, espe-
cially in the elective orthopedic surgery population where 
there is ample time to correct preoperative anemia.19 Oral 
Table 1. Negative Outcomes Associated With Blood 
Transfusions.12,14,15
 1.  Increased length of hospital stay
 2.  Increased rate of discharge to an inpatient facility
 3.  Worse surgical and medical outcomes
 4.  Allergic reactions
 5.  Transfusion-related acute lung injury
 6.  Transfusion-associated circulatory overload
 7.  Venous thromboembolism
 8.  Graft versus host disease
 9.  Immunosuppression
10.  Postoperative infections
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iron is typically preferred over IV iron; however, IV iron is 
indicated for patients who cannot tolerate oral iron; those 
who are experiencing persistent iron losses; patients receiv-
ing EPO; those with iron malabsorption issues, including 
short bowel syndrome; and patients with a short timeline 
before surgery.
Oral iron is best suited for planned TKA or THA surger-
ies when preoperative anemia is identified ahead of time, 
noting that oral iron takes 3 to 6 months to fully replete 
stores.4 One study assessed oral iron (formulation and doses 
not specified) given for a mean of 24.5 weeks preopera-
tively in orthopedic patients with hemoglobin concentra-
tions less than 12 g/dL. Of the 26 patients identified, 24 
(92%) were female; the average age was 67 years; and all 
were undergoing primary THA. Patients responding with 
improved hemoglobin concentrations greater than 12 g/dL 
demonstrated lower transfusion rates than those who did 
not respond (9% of responders [n = 1 of 11] compared with 
33% of nonresponders [n = 5 of 15]; P < 0.05).20 Additional 
labs such as ferritin and transferrin saturation were not 
reported, making it difficult to identify underlying iron defi-
ciency. Challenges to administering oral iron preoperatively 
include proper identification of IDA several months in 
advance of planned surgeries and patient adherence to oral 
iron repletion (Figure 1).
IV iron may be indicated in patients for whom quick 
repletion of stores is desired, such as patients found to have 
IDA in the perioperative setting.21 However, the conve-
nience of administering higher doses over a shorter period 
of time may be offset by concern for hypersensitivity reac-
tions, which although rare, may be life-threatening.22 
Although IV iron provides more timely repletion than oral 
iron, no studies evaluating IV iron alone within the preop-
erative setting were identified.
Use of an ESA, in tandem with oral or IV iron, may help 
increase circulating erythrocytes and improve periopera-
tive outcomes.23,24 A recent meta-analysis highlighted 
results from 26 trials encompassing 3560 orthopedic 
patients receiving an ESA, with or without iron. Of the tri-
als included, 96% (n = 25) combined ESA and iron therapy, 
whereas 35% (n = 9) combined ESA, iron, and preopera-
tive autologous blood donation. All patients included in 
this analysis underwent elective TKA or THA. The ESA 
dosing, schedule, and duration varied among the clinical 
trials, and 20 trials included in the analysis involved par-
ticipant weight and ESA dosing. Globally, doses ranged 
from 225 IU/kg/wk to 2100 IU/kg/wk, with the most con-
sistent dosing regimen of epoetin alfa at 600 IU/kg/wk. 
Most frequently, patients were initiated on therapy from 7 
to 35 days prior to procedure, with the most common start-
ing date cited at 21 days preoperatively (13 trials). 
Administration continued anywhere from 0 to 7 days prior 
to procedure, although continuation of ESA dosing postop-
eratively was rarely seen.23
Five trials used an ESA with IV iron, 2 included a combi-
nation of IV and oral, and the remaining used oral iron sup-
plementation. Commonly, oral iron was initiated at the time 
of epoetin alfa; however, 1 trial did initiate oral iron 2 weeks 
prior to epoetin alfa. Regardless of dose and duration, use of 
oral iron in conjunction with epoetin alfa led to mixed results 
with respect to transfusion requirements. The combination of 
oral iron and epoetin alfa never resulted in more transfusions; 
however, when study protocols allowed for an iron-alone 
arm, these patients often required more blood transfusions 
than those in the combination arm. Administration of IV iron, 
as compared with oral iron, did not alter these findings.
Though the details included in the analysis were not 
fully described in the article, the authors noted that use of 
ESAs led to higher hemoglobin concentrations at discharge. 
This finding did not reach statistical significance and was 
not adjusted for iron administration, baseline hemoglobin 
values, or postoperative differences in hemoglobin. As a 
safety end point for the meta-analysis, thromboembolic 
events were reviewed. The authors found no difference in 
thromboembolic risk when using an ESA; however, mini-
mal data were provided about use of venous thromboembo-
lism prophylaxis. The findings from this meta-analysis 
suggest that ESA use may provide modest benefits in reduc-
ing transfusion rates in the short-term preoperative setting, 
without an increase in adverse events. Interestingly, these 
results are further supported by a recent prospective study 
demonstrating a 10% absolute reduction in transfusions (24 
[13%] vs 5 [3%]; P = 0.0003) after implementation of a 
protocol utilizing ESA + IV iron in anemic preoperative and 
perioperative patients.24 Allotment of 3 to 4 weeks preop-
eratively is necessary to allow the full effects of ESA 
administration to be seen. If used, ESAs should be given 
with iron to maximize the benefit (Figure 1).
Intraoperative Setting
Although outside the scope of this review, numerous inter-
ventions have been studied in the intraoperative setting to 
reduce the need for blood transfusions in orthopedic surgery. 
These consist of nonpharmacological and pharmacological 
strategies. Nonpharmacological modalities include normo-
volemic hemodilution, hypotensive anesthesia, tourniquets, 
bipolar sealants, and Cell Saver. Of these, the use of regional 
and hypotensive anesthesia has the most promising results.12 
Pharmacological strategies include fibrin sealants, desmo-
pressin, thrombin, epinephrine or norepinephrine lavage, 
ε-aminocaproic acid, and tranexamic acid (TXA). To date, 
TXA, administered locally or systemically (IV), has the 
most robust data to support intraoperative use; however, any 
strategy used should be in tandem with preoperative assess-
ment to augment transfusion reduction.12,25 Local and sys-
temic (IV) administration of TXA are both effective 
techniques, without an increased rate of complications.
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Figure 1. Proposed algorithm for identification and correction of perioperative anemia in elective orthopedic surgery patients.
Abbreviations: ESA, erythropoiesis-stimulating agent (epoetin alfa); Hgb, hemoglobin; IV, intravenous; MCV, mean corpuscular volume.
a Refer to Table 2 for specific dosing recommendations.
b American Association of Blood Banks recommends restrictive transfusion for Hgb <8 mg/dL or symptomatic anemia.
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Perioperative Setting
IV iron repletion alone has been evaluated in orthopedic 
surgery in the perioperative setting, including the immedi-
ate preoperative and postoperative periods, for the past 
decade. The iron formulation primarily utilized is iron 
sucrose; however, ferric carboxymaltose has also been 
used. No standard dose exists in this setting; however, total 
doses of 200 to 600 mg of iron sucrose (100-200 mg every 
48 hours for 2-3 doses beginning on the day of admission) 
perioperatively have been reported in studies focusing on 
IV iron.26-31 Studies typically did not report baseline iron 
labs; however, 1 trial specified that patients had near- 
normal iron levels (46.3-53.2 µg/dL), with no significant 
difference between groups as well as normal ferritin and 
transferrin levels.26 No difference has been shown in blood 
transfusion rates (percentage of patients receiving a transfu-
sion) in studies that compared patients receiving IV iron 
alone administered throughout the preoperative and postop-
erative periods with patients not receiving iron.26-28 
Conversely, a retrospective study focusing only on postop-
erative IV iron administration found that its use signifi-
cantly reduced the percentage of patients receiving a 
transfusion (11.5% vs 26.4%, P = 0.001).29 These findings 
are further complicated by subanalyses of 2 of the afore-
mentioned trials showing that patients with preoperative 
hemoglobin concentrations greater than 12 g/dL required 
fewer transfusions compared with those in control 
groups.26,27 This indicates that the ability of IV iron mono-
therapy to maintain hemoglobin concentrations above 
transfusion thresholds may be limited in the short-term set-
ting when patients have lower baseline hemoglobin.
In addition to IV iron, postoperative oral iron has been 
evaluated. One study assessed patients with normal iron 
stores who were treated with oral iron therapy (ferrous sul-
fate 325 mg 4 times daily) or placebo, starting postoperative 
day 2 for the duration of their hospitalization.32 No differ-
ence in transfusion rates or hemoglobin concentrations was 
noted between groups, likely because of the length of time 
it takes to see effects with oral therapy. Additionally, neither 
group experienced a hastened recovery of hemoglobin con-
centrations, and both had similar increases in reticulocyte 
fractions. This study did not assess other outcomes associ-
ated with postoperative anemia. IV iron may be preferred in 
the acute perioperative setting because it may allow rapid 
administration and use of iron despite the presence of 
inflammatory processes, which mitigate the body’s ability 
to utilize iron stores.
Discussion
A focus on limiting blood transfusions secondary to postop-
erative anemia in elective orthopedic surgery patients is 
essential to improve patient outcomes. Measures can be 
taken to reduce blood transfusions after elective orthopedic 
surgery, including preoperative screening and treatment of 
underlying anemia and use of iron or ESAs to improve peri-
operative anemia.
Postoperative anemia is easily explained by acute blood 
loss and the inflammatory state induced by surgery itself, 
leading to altered erythropoiesis and iron metabolism, and 
reduced availability of iron when the body attempts to com-
pensate. In patients undergoing elective THA or TKA, the 
goal of limiting blood transfusions begins in the preopera-
tive period, where screening and assessment are crucial. 
The Network for Advancement of Transfusion Alternatives 
(NATA) recommends that screening and correction of pre-
operative anemia take place 28 days or more prior to 
surgery.3 As erythropoiesis and iron play an important role, 
strategies to overcome perioperative anemia include the use 
of iron and ESAs. If patients are found to be iron deficient, 
oral iron replacement is adequate in treating this underlying 
deficiency, provided there is adequate time prior to surgery. 
IV iron should be reserved for patients in whom oral ther-
apy is not indicated. If patients have deficiencies in folate or 
vitamin B12, these should also be treated prior to surgery. 
For patients who do not respond to iron and those without 
nutritional deficiencies, ESA therapy may be implemented 
to correct the anemia. Regardless of the plan for preopera-
tive autologous blood donation, the combination of IV iron 
and epoetin alfa has demonstrated the most favorable results 
when used in patients with preoperative anemia and should 
be considered in patients not responding to ESA therapy 
alone.
Agents used and dosing strategies varied throughout the 
literature; however, appropriate dosing for each of the 
agents used should be applied and may be institution spe-
cific. Table 2 outlines evidence-supported agents, dosing 
utilized, and estimated time to peak effect. Institution for-
mulary and infusion protocols typically dictate which iron 
formulation is used and how it is given. Regarding ESA 
dosing, the literature and clinical trials suggest a preopera-
tive hemoglobin level of 10 to 13 g/dL as a trigger for ESA 
therapy, but expected blood loss should also play a role in 
the decision to use an ESA.23 To date, clinical trials have 
only used epoetin alfa; however, darbepoetin alfa may offer 
the advantage of a pre-filled syringe alternative. Darbepoetin 
alfa also has a 3-fold longer half-life than epoetin alfa and 
may be dosed less frequently.33 Nevertheless, clinical ben-
efits of darbepoetin alfa in the setting of elective orthopedic 
surgery remain to be evaluated.
Although the agents discussed are being evaluated for 
short-term use, adverse events are important to consider. 
Oral iron commonly causes constipation, dark stools, stom-
ach irritation, and nausea. Additionally, to maximize absorp-
tion, oral iron needs an acidic environment and should be 
taken on an empty stomach or with an acidifier such as vita-
min C, which further increases some gastrointestinal adverse 
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effects. Another consideration in postoperative patients and 
some preoperative patients is that many would also be 
receiving opioids for pain relief, which may compound con-
stipation in patients receiving oral iron. IV iron is most nota-
bly associated with hypersensitivity reactions, including 
anaphylaxis; however, this is more common with older for-
mulations or fast rates of administration. Other possible 
adverse events include hypotension, headache, nausea, and 
muscle cramps.22 In orthopedic surgery studies, no differ-
ences were found between IV iron and comparators with 
regard to adverse events, and no severe adverse reactions to 
IV iron were noted.
ESAs are also associated with risks, most notably a 
boxed warning for cardiovascular events, including throm-
boembolic events. Aggressive venous thromboembolism 
prophylaxis following orthopedic surgeries should always 
be done, especially when using ESAs perioperatively. Other 
possible adverse effects include allergic reactions, hyper-
tension, and gastrointestinal effects, including nausea and 
vomiting. With ESA use, weekly hemoglobin values should 
be monitored for rapid changes in concentrations and to 
assess the need for changes in dosing or frequency. If hemo-
globin concentrations reach 13 mg/dL for men or 12 mg/dL 
for women, ESA therapy should be discontinued.3 ESAs 
should be used with caution in chronic kidney disease and 
oncology patients. These patients are at higher risk of 
thromboembolic events and may have a lower threshold for 
ESA discontinuation (hemoglobin 10 to 11 mg/dL).34 Iron 
deficiency, chronic inflammation, and underlying malig-
nancy diminish response to ESAs. Iron studies should be 
completed prior to ESA use, and deficiencies should be 
corrected.
Finally, cost often accompanies agent selection, with 
oral iron as the least-expensive option, followed by IV iron, 
and then ESAs. A recent analysis demonstrated a reduction 
in blood transfusions with ESA therapy; however, use of 
ESAs in this analysis proved cost-prohibitive. ESA use was 
associated with an increased cost per patient of €785 
(roughly US $860) and more than €7000 (roughly US 
$7650) per unit of blood transfusion avoided. Although the 
authors speculated that this could be partly a result of the 
strict transfusion protocol in place at their institution, care-
ful cost considerations must be evaluated prior to ESA 
use.35 IV iron, on the other hand, may be associated with 
neutral costs or modest cost savings, as demonstrated by 
one study.29 This can likely be attributed to the fact that IV 
iron significantly reduced the percentage of patients trans-
fused in this study.
Multiple facets should be evaluated when considering 
the use of oral or IV iron or an ESA to reduce blood trans-
fusions in orthopedic surgery patients. The studies 
reviewed were limited by nonstandardized dosing, differ-
ences in timing of therapy initiation, and mixed reports of 
efficacy. Based on understanding of drug mechanisms and 
onset of action, pathophysiology of anemia, and available 
evidence, an assessment of findings and a proposed treat-
ment algorithm is outlined in Figure 1, with dosing strate-
gies outlined in Table 2. This algorithm is designed to 
serve only as a guide; clinical considerations, patient- 
specific factors, and individualized dosing should be eval-
uated. In addition to iron and ESAs, additional measures 
should be taken to reduce transfusions, including cessa-
tion of antiplatelet and anticoagulant medications prior to 
planned surgery and intraoperative strategies such as local 
or systemic TXA. Finally, strict transfusion protocols 
should be in place according to AABB guidelines (hemo-
globin <8 g/dL or symptoms present) because they have 
been shown to reduce transfusion rates and potentially 
reduce mortality. With careful planning and strategic 
implementation of interventions such as iron supplemen-
tation and use of ESAs, blood transfusions can be mini-
mized in patients undergoing elective orthopedic surgery, 
leading to reduced hospital cost and improved patient 
outcomes.
Table 2. Summary of Iron and ESA Dosing and Expected Time to Peak Effect for the Correction of Perioperative Anemia.
Agent Suggested Dosing Based on Clinical Trialsa Expected Time to Peak Effect
Ferrous sulfate (po) 325 mg twice to thrice dailyb 3 To 6 Monthsc
Iron sucrose (IV) •• Preoperative with ESA: 200 mg once when ESA given
•• Perioperative: 100-200 mg every 48 hours for 2-3 
dosesd during hospital admission
2 To 4 weekse
Ferric carboxymaltose (IV) 600 mg onced 2 To 4 weekse
Epoetin alfa (sc) 600 IU/kg/wkf 2 To 4 weekse
Abbreviations: ESA, erythropoiesis-stimulating agent (epoetin alfa); Hgb, hemoglobin; IV, intravenous.
aDosing schemes varied widely across clinical trials; minimum total effective doses should be utilized.
bStarted 3 to 6 months prior to planned surgery.
cMay see some effect within 3 weeks.
dStarted on day of admission, consider equivalent formulary IV iron.
eMay see some effect within 2 to 7 days.
fSingle or repeat doses may be warranted; close Hgb monitoring required; consider equivalent formulary ESA.
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